WuXi Biologics: Shares Moving Up Since July Likely Due to Sector Rotation Into Healthcare
WuXi Biologics' share price has increased more than 15% since the end of July.
WuXi Biologics (Cayman) Inc 02269
Bulls Say, Bears Say
Bulls
The Biosecure Act is repealed or becomes irrelevant, leading to more pipeline projects in North America.
Bears
The Biosecure Act forces WuXi to abandon US contracts in its pipeline.
News
-
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
-
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
-
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
-
WuXi AppTec Shares Rally Amid Sectorwide Gains After Tech Selloff, China Policy Support
-
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
-
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
-
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
-
WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares
Trading Information
- Previous Close Price
- HK$45.72
- Day Range
- HK$44.42–46.40
- 52-Week Range
- HK$28.48–48.78
- Bid/Ask
- HK$45.12 / HK$45.14
- Shares Outstanding
- 4.11B
- Market Cap
- HK$185.36B
- Volume/Avg
- 21M / 33M
Key Statistics
- Price/Earnings (Normalized)
- 32.85
- Price/Sales
- 7.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.92%
Company Profile
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 13,252
- Website
- https://www.wuxibiologics.com
Competitors
Valuation
|
Metric
|
02269
|
CRL
|
IQV
|
|---|---|---|---|
Price/Earnings (Normalized) | 32.85 | 28.00 | 18.98 |
Price/Book Value | 3.71 | 4.71 | 6.31 |
Price/Sales | 7.98 | 3.42 | 2.37 |
Price/Cash Flow | 21.97 | 19.92 | 15.38 |
Price/Earnings
02269
CRL
IQV
Financial Strength
|
Metric
|
02269
|
CRL
|
IQV
|
|---|---|---|---|
Quick Ratio | 2.96 | 0.80 | 0.62 |
Current Ratio | 3.39 | 1.35 | 0.71 |
Interest Coverage | 48.97 | −0.77 | 2.99 |
Quick Ratio
02269
CRL
IQV
Profitability
|
Metric
|
02269
|
CRL
|
IQV
|
|---|---|---|---|
Return on Assets (Normalized) | 9.34% | 4.56% | 7.22% |
Return on Equity (Normalized) | 13.16% | 10.89% | 34.41% |
Return on Invested Capital (Normalized) | 10.10% | 7.04% | 12.37% |
Return on Assets
02269
CRL
IQV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|b&@?M# | LOCK|%g%? | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!r!RNjx | LOCK|v!!<! | $83B | |||
| argenx SE ADR
ARGX
| LOCK|%!CFqD | LOCK|Rn& | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|D!gGl%m | LOCK|?L!^@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|LQ@GJw | LOCK|sd | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@NcRy@! | LOCK|$ky% | $31B | |||
| Moderna Inc
MRNA
| LOCK|&xxt#@g | LOCK|%dS | $25B | |||
| Incyte Corp
INCY
| LOCK|>YqF!tH | LOCK|XS# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|?<&j@Z | LOCK|S? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&x?wr^ | LOCK|pTC | $16B |
United States